Zymeworks Financial Statements From 2010 to 2025

ZYME Stock  USD 12.58  0.33  2.69%   
Zymeworks Common financial statements provide useful quarterly and yearly information to potential Zymeworks Common Stock investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Zymeworks Common financial statements helps investors assess Zymeworks Common's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Zymeworks Common's valuation are summarized below:
Gross Profit
-60.2 M
Profit Margin
(1.61)
Market Capitalization
852.3 M
Enterprise Value Revenue
8.4445
Revenue
76.3 M
There are over one hundred nineteen available fundamental gauges for Zymeworks Common Stock, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Zymeworks Common's prevalent performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of March 17, 2025, Market Cap is expected to decline to about 788.7 M. The current year's Enterprise Value is expected to grow to about (44.2 B)

Zymeworks Common Total Revenue

78.71 Million

Check Zymeworks Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zymeworks Common's main balance sheet or income statement drivers, such as Interest Expense of 5.8 M, Selling General Administrative of 64.6 B or Total Revenue of 78.7 M, as well as many indicators such as Price To Sales Ratio of 13.82, Dividend Yield of 0.0 or PTB Ratio of 0.0031. Zymeworks financial statements analysis is a perfect complement when working with Zymeworks Common Valuation or Volatility modules.
  
Check out the analysis of Zymeworks Common Correlation against competitors.

Zymeworks Common Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets486.2 B463.1 B59.5 B
Slightly volatile
Other Current Liabilities65.8 B62.7 B8.1 B
Slightly volatile
Total Current Liabilities92.7 B88.3 B11.3 B
Slightly volatile
Other Liabilities22.5 M40.7 M17.7 M
Slightly volatile
Property Plant And Equipment Net36 B34.3 B4.4 B
Slightly volatile
Accounts Payable4.6 M3.9 M3.6 M
Slightly volatile
Cash69.4 B66.1 B8.6 B
Slightly volatile
Non Current Assets Total170.8 B162.6 B20.9 B
Slightly volatile
Cash And Short Term Investments237.1 B225.8 B29.1 B
Slightly volatile
Net Receivables58.6 B55.8 B7.2 B
Slightly volatile
Common Stock Shares Outstanding46 M75.9 M36.6 M
Slightly volatile
Inventory0.80.90.9813
Slightly volatile
Other Current Assets19.8 B18.9 B2.4 B
Slightly volatile
Total Liabilities130.5 B124.3 B16 B
Slightly volatile
Short and Long Term Debt67.7 K71.3 K326.1 K
Very volatile
Total Current Assets315.5 B300.5 B38.7 B
Slightly volatile
Short Term Debt4.3 M2.7 MM
Slightly volatile
Intangible Assets4.3 M4.6 M11.8 M
Slightly volatile
Common Stock1.1 TT130.4 B
Slightly volatile
Property Plant Equipment57.5 M54.8 M17.7 M
Slightly volatile
Short and Long Term Debt Total19.4 B18.5 B2.4 B
Slightly volatile
Current Deferred Revenue26.9 B25.6 B3.3 B
Slightly volatile
Other Assets30.9 M39.9 M20.8 M
Slightly volatile
Common Stock Total Equity894.9 M852.3 M393.5 M
Slightly volatile
Short Term Investments167.7 B159.7 B20.5 B
Slightly volatile
Non Current Liabilities Total37.8 B36 B4.6 B
Slightly volatile
Capital Surpluse238.7 M227.4 M85.8 M
Slightly volatile
Deferred Long Term Liabilities22.5 M20.3 M14.1 M
Slightly volatile
Property Plant And Equipment Gross34.9 M52.1 M21.8 M
Slightly volatile
Long Term Debt44.5 K46.8 KM
Slightly volatile
Good Will9.6 M10.8 M11.8 M
Slightly volatile
Long Term Debt Total39.3 K41.4 KM
Slightly volatile
Capital Lease Obligations15.9 M18.5 M9.1 M
Slightly volatile
Preferred Stock Total Equity47.1 M53 M57.8 M
Slightly volatile
Non Current Liabilities Other850.2 K895 K3.3 M
Slightly volatile
Net Invested Capital352.9 M338.8 M233.4 M
Slightly volatile
Net Working Capital294.9 M212.2 M186.5 M
Slightly volatile
Capital Stock812.9 MB534.1 M
Slightly volatile
Deferred Long Term Asset Charges716.1 K1.4 M560.2 K
Slightly volatile

Zymeworks Common Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense5.8 M4.1 M3.8 M
Slightly volatile
Selling General Administrative64.6 B61.5 B7.9 B
Slightly volatile
Total Revenue78.7 M76.3 M54.5 M
Slightly volatile
Other Operating Expenses159.6 M213.4 M113.3 M
Slightly volatile
Research Development114.4 M134.6 M81.8 M
Slightly volatile
Cost Of Revenue110.8 M164.4 M82.8 M
Slightly volatile
Total Operating Expenses145.3 M213.4 M103.5 M
Slightly volatile
Interest Income20.9 M19.9 M5.4 M
Slightly volatile
Non Recurring1.1 M883.2 K841.2 K
Pretty Stable
Reconciled Depreciation10.5 M11.2 M6.7 M
Slightly volatile
Selling And Marketing Expenses33.8 B61.4 BB
Slightly volatile

Zymeworks Common Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation14.2 M17.8 M9.9 M
Slightly volatile
Begin Period Cash Flow165.4 B157.6 B20.3 B
Slightly volatile
Depreciation9.1 B8.7 B1.1 B
Slightly volatile
Capital Expenditures2.9 M3.1 M4.4 M
Slightly volatile
End Period Cash Flow69.4 B66.1 B8.6 B
Slightly volatile
Dividends Paid983.1 M936.3 M273.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13.8214.552363.9853
Slightly volatile
Days Sales Outstanding280.3 K267 K34.5 K
Slightly volatile
Book Value Per Share4.7 K4.5 K576
Slightly volatile
Stock Based Compensation To Revenue0.440.23320.3857
Very volatile
Capex To Depreciation0.260.271.1436
Pretty Stable
Days Of Inventory On Hand0.00.00.0
Slightly volatile
Payables Turnover17.0820.7217.1929
Slightly volatile
Sales General And Administrative To Revenue846806105
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue3.521.76434.3112
Slightly volatile
Capex To Revenue0.05860.06170.1803
Pretty Stable
Cash Per Share3.1 KK385
Slightly volatile
Days Payables Outstanding24.6318.2432.0436
Slightly volatile
Intangibles To Total Assets0.0340.03580.0734
Pretty Stable
Current Ratio3.913.40284.7517
Pretty Stable
Receivables Turnover0.00130.001413.3698
Very volatile
Capex Per Share0.05060.05330.1103
Slightly volatile
Revenue Per Share1.151.0061.0862
Slightly volatile
Interest Debt Per Share25624431.35
Slightly volatile
Debt To Assets0.02360.03990.02
Slightly volatile
Graham Number14.4116.2117.6753
Slightly volatile
Operating Cycle280.3 K267 K34.5 K
Slightly volatile
Days Of Payables Outstanding24.6318.2432.0436
Slightly volatile
Ebt Per Ebit1.080.85050.9967
Slightly volatile
Long Term Debt To Capitalization0.04850.05110.1697
Slightly volatile
Quick Ratio3.913.40284.7517
Pretty Stable
Net Income Per E B T0.791.05220.9838
Slightly volatile
Cash Ratio0.710.74872.773
Slightly volatile
Days Of Inventory Outstanding0.00.00.0
Slightly volatile
Days Of Sales Outstanding280.3 K267 K34.5 K
Slightly volatile
Fixed Asset Turnover0.00210.00223.8262
Pretty Stable
Debt Ratio0.02360.03990.02
Slightly volatile
Price Sales Ratio13.8214.552363.9853
Slightly volatile
Asset Turnover2.0E-42.0E-40.1435
Pretty Stable

Zymeworks Common Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap788.7 M1.1 B612.8 M
Slightly volatile

Zymeworks Fundamental Market Drivers

Cash And Short Term Investments225.8 B

Zymeworks Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Zymeworks Common Financial Statements

Zymeworks Common stakeholders use historical fundamental indicators, such as Zymeworks Common's revenue or net income, to determine how well the company is positioned to perform in the future. Although Zymeworks Common investors may analyze each financial statement separately, they are all interrelated. For example, changes in Zymeworks Common's assets and liabilities are reflected in the revenues and expenses on Zymeworks Common's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Zymeworks Common Stock. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue25.6 B26.9 B
Total Revenue76.3 M78.7 M
Cost Of Revenue164.4 M110.8 M
Stock Based Compensation To Revenue 0.23  0.44 
Sales General And Administrative To Revenue 806.07  846.37 
Research And Ddevelopement To Revenue 1.76  3.52 
Capex To Revenue 0.06  0.06 
Revenue Per Share 1.01  1.15 
Ebit Per Revenue(1.80)(1.89)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:
Check out the analysis of Zymeworks Common Correlation against competitors.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.62)
Revenue Per Share
1.006
Quarterly Revenue Growth
0.833
Return On Assets
(0.15)
Return On Equity
(0.31)
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.